SLC5A2 and hydrops fetalis: For example, the risk‐benefit profile of SGLT‐2 inhibitors may potentially be better understood by monitoring rates of changes in outcomes like ketoacidosis and HF admissions among commercially insured patients (who have rapidly rising exposure to SGLT‐2 inhibitors) compared to Medicare patients (who are adopting this drug class much more slowly).19